Metabolic dysfunction-associated steatohepatitis (MASH) Clinical Trials

11 recruitingLast updated: June 19, 2026

There are 11 actively recruiting metabolic dysfunction-associated steatohepatitis (mash) clinical trials across 42 countries. Studies span Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Barcelona, Spain, San Antonio, Texas, United States, Brownsville, Texas, United States. Updated daily from ClinicalTrials.gov.


Metabolic dysfunction-associated steatohepatitis (MASH) Trials at a Glance

11 actively recruiting trials for metabolic dysfunction-associated steatohepatitis (mash) are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Barcelona, San Antonio, and Brownsville. Lead sponsors running metabolic dysfunction-associated steatohepatitis (mash) studies include Corcept Therapeutics, Boehringer Ingelheim, and Ali Aminian.

Browse metabolic dysfunction-associated steatohepatitis (mash) trials by phase

Treatments under study

About Metabolic dysfunction-associated steatohepatitis (MASH) Clinical Trials

Looking for clinical trials for Metabolic dysfunction-associated steatohepatitis (MASH)? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metabolic dysfunction-associated steatohepatitis (MASH) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metabolic dysfunction-associated steatohepatitis (MASH) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled303 locationsNCT06419374
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 2

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Metabolic dysfunction-associated steatohepatitis (MASH)
Regeneron Pharmaceuticals120 enrolled71 locationsNCT05519475
Recruiting
Phase 2

A Study of CS060380 Tablets in Patients With MASH and Obesity

Metabolic dysfunction-associated steatohepatitis (MASH)Obesity
Cascade Pharmaceuticals, Inc120 enrolled12 locationsNCT07466017
Recruiting
Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 2

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Metabolic dysfunction-associated steatohepatitis (MASH)
The United Bio-Technology (Hengqin) Co., Ltd.156 enrolled1 locationNCT07145151
Recruiting
Phase 2

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Metabolic dysfunction-associated steatohepatitis (MASH)
Innovent Biologics (Suzhou) Co. Ltd.165 enrolled1 locationNCT06937749
Recruiting

Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study

Metabolic dysfunction-associated steatohepatitis (MASH)
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau25 enrolled2 locationsNCT07188220
Recruiting
Phase 4

Fibrosis Lessens After Metabolic Surgery

Metabolic dysfunction-associated steatohepatitis (MASH)ObesityNon-Alcoholic Fatty Liver Disease+2 more
Ali Aminian120 enrolled22 locationsNCT06374875
Recruiting
Phase 2

A Phase 2a double-blind, randomised, placebo-controlled, parallel group study to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of GL0034 in adults with at-risk metabolic dysfunction-associated steatohepatitis (MASH)

Metabolic dysfunction-associated steatohepatitis (MASH)
Sun Pharmaceuticals Ltd60 enrolled1 locationACTRN12625000241437